Clinical Trial

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Name: A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis — clinical trial record (NCT07234591)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Record status

This record was last updated November 18, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.

Summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

Trial Details

NCT Number	NCT07234591
Lead Sponsor	Usynova Pharmaceuticals Ltd.
Conditions	Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Enrollment	140 participants
Start Date	2025-10-21
Primary Completion	2026-04-30 (estimated)
Study Completion	2026-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-18